Data gathered: November 11
Alternative Data for Calidi Biotherapeutics
Alternative Data | Value | 3m Change | Trend | Benchmark | |
---|---|---|---|---|---|
Job Posts | N/A | Sign up | Sign up | Sign up | |
Sentiment | 100 | Sign up | Sign up | Sign up | |
Webpage traffic | 1,000 | Sign up | Sign up | Sign up | |
Employee Rating | 80 | Sign up | Sign up | Sign up | |
Google Trends | N/A | Sign up | Sign up | Sign up | |
Patents | N/A | Sign up | Sign up | Sign up | |
4chan Mentions | N/A | Sign up | Sign up | Sign up | |
Reddit Mentions | N/A | Sign up | Sign up | Sign up | |
Stocktwits Mentions | 7 | Sign up | Sign up | Sign up | |
Stocktwits Subscribers | 743 | Sign up | Sign up | Sign up | |
Twitter Followers | 73 | Sign up | Sign up | Sign up | |
Twitter Mentions | 98 | Sign up | Sign up | Sign up | |
News Mentions | N/A | Sign up | Sign up | Sign up | |
Customer reviews | N/A | Sign up | Sign up | Sign up | |
Business Outlook | 100 | Sign up | Sign up | Sign up | |
Linkedin Employees | 34 | Sign up | Sign up | Sign up |
About Calidi Biotherapeutics
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors.
Price | $1.68 |
Target Price | Sign up |
Volume | 2,150,000 |
Market Cap | $20M |
Year Range | $0.83 - $7.78 |
Dividend Yield | 0% |
Analyst Rating | 0% buy |
Industry | Biotechnology |
In the news
Warning: CLDI is at high risk of performing badlyNovember 2 - Seeking Alpha |
|
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVOctober 24 - Yahoo |
|
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific ConferencesOctober 23 - Yahoo |
|
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private PlacementOctober 23 - GlobeNewswire |
|
Comparing Cyclo Therapeutics (NASDAQ:CYTH) and Calidi Biotherapeutics (NYSE:CLDI)October 19 - ETF Daily News |
|
Calidi Biotherapeutics Faces Warrant Delisting by NYSEOctober 19 - Yahoo |
Financial performance View All
Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
---|---|---|---|---|---|---|
Q2 '24 | 0 | 3.6M | -3.6M | -5.8M | 0 | -1.400 |
Q1 '24 | 0 | 4M | -4M | -7.2M | 0 | -0.200 |
Q4 '23 | 170,000 | 5.9M | -5.7M | -8.2M | 0 | -0.480 |
Q3 '23 | 0 | 4M | -4.3M | -2M | 0 | -0.140 |
Q2 '23 | 3.3M | 3.4M | -17,000 | -13M | 0 | -0.432 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Calidi Biotherapeutics (CLDI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Calidi Biotherapeutics?
The Market Cap of Calidi Biotherapeutics is $20M.
What is the current stock price of Calidi Biotherapeutics?
Currently, the price of one share of Calidi Biotherapeutics stock is $1.68.
How can I analyze the CLDI stock price chart for investment decisions?
The CLDI stock price chart above provides a comprehensive visual representation of Calidi Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Calidi Biotherapeutics shares. Our platform offers an up-to-date CLDI stock price chart, along with technical data analysis and alternative data insights.
Does CLDI offer dividends to its shareholders?
As of our latest update, Calidi Biotherapeutics (CLDI) does not offer dividends to its shareholders. Investors interested in Calidi Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Calidi Biotherapeutics?
Some of the similar stocks of Calidi Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.